Portfolio Details

NeoChord, Inc.

NeoChord Logo
Current

NeoChord is a medical technology company focused on advancing the treatment of mitral regurgitation.

Baird Capital invests in the Technology & Services sector, including tech business services, as well as businesses that provide services directly or indirectly to the healthcare industry. Baird Capital and predecessor entities previously made investments in MedTech including investments in medical tools (e.g., DNA analysis), Medical devices (e.g., bladder control, heart valves, surgical robotics, etc.) and certain areas of Industrials and Consumer Products. 

Learn more about the company
NeoChord Logo
Current
Team
Venture Capital
Invested Date
June 2015
Status
Active
Location
U.S.

Share

See All Transactions

Related Content

Operating room lights
NeoChord Announces Successful In-Human Procedure

Baird Capital portfolio company NeoChord recently announced successful completion of the first-in-human procedure with the NeoChord NeXuS Transcatheter Mitral Chordal Repair technology (TMVr).